000			01490 a2200385 4500
005			20250511203319.0
264		0	_c19920211
008			199202s 0 0 eng d
022			_a0340-7004
024	7		_a10.1007/BF01741340 _2doi
040			_aNLM _beng _cNLM
100	1		_aBartik, M M
245	0	0	_aEnhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers. _h[electronic resource]
260			_bCancer immunology, immunotherapy : CII _c1991
300			_a79-89 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAnimals
650	0	4	_aCD4-CD8 Ratio
650	0	4	_aCD8 Antigens _xanalysis
650	0	4	_aCytotoxicity, Immunologic _xdrug effects
650	0	4	_aFemale
650	0	4	_aInterleukin-2 _xpharmacology
650	0	4	_aLymphocyte Activation
650	0	4	_aMelphalan _xadministration & dosage
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aPlasmacytoma _xdrug therapy
650	0	4	_aRecombinant Proteins _xpharmacology
650	0	4	_aT-Lymphocyte Subsets _xdrug effects
650	0	4	_aThymoma _ximmunology
700	1		_aBaumgartel-Scofield, B A
700	1		_aMokyr, M B
773	0		_tCancer immunology, immunotherapy : CII _gvol. 34 _gno. 2 _gp. 79-89
856	4	0	_uhttps://doi.org/10.1007/BF01741340 _zAvailable from publisher's website
999			_c1767216 _d1767216